9. COVID Steroid 2 Trial Group, Munch MW, Myatra SN, et al. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial. JAMA. 2021;326(18):1807-1817.

10. Yu LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398(10303):843-855.

11. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645.

12. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407-1418.

13. Wiltz JL, Feehan AK, Molinari NM, et al. Racial and ethnic disparities in receipt of medications for treatment of COVID-19 — United States, March 2020–August 2021. MMWR Morb Mortal Wkly Rep.2022;71(3):96-102. 

14. Swaminathan A, Essien UR, Choo E. Molnupiravir: another COVID-19 treatment, another opportunity to recognize inequity. STAT News. 2021 Nov. https://www.statnews.com/2021/11/03/another-covid-19-treatment-another-opportunity-to-recognize-inequity/.

Dr. Swaminathan is an assistant clinical professor of Emergency Medicine at St. Joseph’s Hospital in Paterson, New Jersey.